静脉-动脉体外膜氧合作为心脏移植桥接的可行选择
该回顾性队列研究利用UNOS数据库(1999-2018)分析26,918例心脏移植受者,比较ECMO桥接(146例,0.5%)与其他机械循环支持或无支持患者的生存。主要终点为16.7年限制平均生存时间,ECMO桥接受者估计生存比无机械支持者少16.6个月,但作者认为ECMO桥接仍是可行选择,不应排除移植候选资格。
要点
- ECMO桥接心脏移植占0.5%(146/26,918),术后16.7年限制平均生存时间较无机械支持者少16.6个月。
- 与LVAD、IABP、BiVAD桥接相比,ECMO桥接的估计限制平均生存时间更低。
- ECMO桥接与RVAD或全人工心脏桥接的生存时间相似。
核心结论
- ECMO桥接心脏移植受者估计生存比无机械循环支持受者少16.6个月。
- ECMO桥接心脏移植仍是可行选择,此类患者应被考虑为移植候选者。
研究设计与样本
- 回顾性分析UNOS数据库1999年1月1日至2018年3月31日的心脏移植受者。
- 共纳入26,918例受者,按移植前机械循环支持类型分组,比较ECMO桥接(146例)与其他支持或无支持患者。
- 主要终点为16.7年限制平均生存时间。
主要发现
- 26,918例受者中,15,076例(56.0%)无移植前机械支持,9,321例(34.6%)使用LVAD,53例(0.2%)使用RVAD,258例(1.0%)使用全人工心脏,686例(2.6%)使用双心室辅助装置,1,378例(5.1%)使用IABP,146例(0.5%)使用ECMO。
- 术后16.7年内,与ECMO桥接相比,无机械支持者调整后限制平均生存时间高16.6个月(14.0-19.4),LVAD桥接者高16.5个月(99%CI 13.9-19.2),IABP桥接者高11.2个月(8.3-14.7),BiVAD桥接者高6.6个月(3.6-10.3)。
- RVAD或全人工心脏桥接者的限制平均生存时间与ECMO桥接者相似。
临床怎么用
- ECMO可作为心脏移植的桥接手段,不应仅因使用ECMO而排除移植候选资格。
- ECMO桥接者的估计生存低于无机械支持、LVAD、IABP或BiVAD桥接者,需综合评估获益与风险。
局限性
- 回顾性数据库研究,可能存在选择偏倚和混杂因素。
- ECMO桥接组样本量较小(146例),结果解释需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Venoarterial extracorporeal membrane oxygenation is a rescue therapy for patients in cardiogenic shock. We hypothesize that patients bridged to heart transplant with extracorporeal membrane oxygenation have decreased survival. METHODS: The United Network of Organ Sharing database was retrospectively reviewed from January 1, 1999, to March 31, 2018, for heart transplant recipients. Recipients bridged with any form of mechanical support and those without support were compared with recipients bridged with extracorporeal membrane oxygenation. The primary end point was restricted mean survival time through 16.7 years. RESULTS: Of 26,918 recipients, 15,076 required no pretransplant mechanical support (56.0%). Support patients included 9321 with left ventricular assist devices (34.6%), 53 with right ventricular assist devices (0.2%), 258 with total artificial hearts (1.0%), 686 with biventricular assist devices (2.6%), 1378 with intra-aortic balloon pumps (5.1%), and 146 who required extracorporeal membrane oxygenation (0.5%). In the first 16.7 years post-transplant, compared with recipients bridged with extracorporeal membrane oxygenation, estimated adjusted restricted mean survival time was higher in patients who required no mechanical support (16.6 months [14.0-19.4]) and patients with a left ventricular assist device (16.5 months [99% confidence interval, 13.9-19.2]), an intra-aortic balloon pump (11.2 months [8.3-14.7]), or a biventricular assist device (6.6 months [3.6-10.3]). Restricted mean survival time in patients with a right ventricular assist device or a total artificial heart was similar to patients with extracorporeal membrane oxygenation. CONCLUSIONS: Recipients bridged with extracorporeal membrane oxygenation were estimated to survive 16.6 months less than nonmechanical circulatory support recipients. Bridge to heart transplant with extracorporeal membrane oxygenation is a viable option, and these patients should be considered transplant candidates.
引用
- Carter KT, O'Brien R, Larson SB, et al. Venoarterial extracorporeal membrane oxygenation is a viable option as a bridge to heart transplant. J Thorac Cardiovasc Surg. 2020. PMID: 32928549. doi:10.1016/j.jtcvs.2020.08.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。